Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bank of America Securities Sticks to Their Sell Rating for SAGE Therapeutics (SAGE)

Tipranks - Tipranks - Tue May 20, 2025

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Sell rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $6.89.

Confident Investing Starts Here:

According to TipRanks, Ahmad is an analyst with an average return of -5.3% and a 43.00% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Alnylam Pharma.

Currently, the analyst consensus on SAGE Therapeutics is a Hold with an average price target of $8.75.

See Insiders’ Hot Stocks on TipRanks >>

Based on SAGE Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $14.06 million and a GAAP net loss of $62.21 million. In comparison, last year the company earned a revenue of $7.9 million and had a GAAP net loss of $108.48 million

Read More on SAGE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).